XROMI
Clinical safety rating: caution
Comprehensive clinical and safety monograph for XROMI (XROMI).
XROMI is a selective estrogen receptor downregulator (SERD) that binds to estrogen receptors, inducing a conformational change leading to receptor degradation and inhibition of estrogen signaling in breast cancer cells.
| Metabolism | Primarily metabolized by CYP3A4 and to a lesser extent by CYP2C8. |
| Excretion | Renal: 80-90% unchanged; Biliary/Fecal: 10-20% as metabolites. |
| Half-life | Terminal elimination half-life: 18-24 hours. In moderate renal impairment (CrCl 30-60 mL/min), half-life increases to 30-40 hours; in severe impairment (CrCl <30 mL/min), up to 60 hours, requiring dose adjustment. |
| Protein binding | 95-98% bound primarily to albumin; also binds to alpha-1-acid glycoprotein. |
| Volume of Distribution | Vd: 0.8-1.2 L/kg (approximately 60-84 L in a 70 kg adult), indicating extensive tissue distribution. |
| Bioavailability | Oral: 50-70% due to first-pass metabolism. |
| Onset of Action | Oral: 1-2 hours; IV: 15-30 minutes. |
| Duration of Action | Oral: 12-24 hours; IV: 6-12 hours. Duration may be prolonged in hepatic impairment due to reduced clearance. |
| Molecular Weight | 320.4 |
| Action Class | Proton pump inhibitors |
| Brand Substitutes | Kemopraz 20mg Capsule, Omee Capsule, Omecip Capsule, Omesec 20 Capsule, Rizole 40mg Capsule, Promisec 40mg Capsule, Estom 40mg Capsule, Zolcer 40mg Capsule, Ozol 40mg Capsule |
5 mg orally once daily.
| Dosage form | SOLUTION |
| Renal impairment | GFR 30-89 mL/min: no adjustment; GFR <30 mL/min: not recommended. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose to 2.5 mg once daily; Child-Pugh C: not recommended. |
| Pediatric use | Not established; use not recommended in patients <18 years. |
| Geriatric use | Initiate at 2.5 mg once daily; titrate based on tolerability. |
| 1st trimester | Avoid due to teratogenic potential in animal studies; limited human data. |
| 2nd trimester | Use only if maternal benefit outweighs fetal risk; monitor fetal growth. |
| 3rd trimester | Avoid near term due to risk of adverse effects (e.g., premature closure of ductus arteriosus). |
Clinical note
Comprehensive clinical and safety monograph for XROMI (XROMI).
| Placental transfer | Crosses placenta; detected in fetal plasma at 10-50% of maternal levels in animal studies. |
| Breastfeeding | Excreted in breast milk in low concentrations; potential for adverse effects in infant (e.g., diarrhea, rash). Use with caution, monitor infant. |
| Lactation Rating |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
Hypersensitivity to XROMISevere hepatic impairmentConcomitant use with strong CYP3A4 inhibitors
| Precautions | Embryo-fetal toxicity: Can cause fetal harm; advise females of reproductive potential to use effective contraception., Dyslipidemia: Monitor serum cholesterol levels during treatment., Musculoskeletal pain: Arthralgia and myalgia common; manage symptomatically., Hot flashes and night sweats: Common; manage symptomatically. |
| Food/Dietary | Avoid grapefruit and grapefruit juice during treatment as it increases systemic exposure. High-fat meals may delay absorption; take on empty stomach for consistent effect. Limit caffeine intake as it may potentiate adverse effects like tachycardia. |
Loading safety data…
| L3 (Moderately Safe) |
| Teratogenic Risk | XROMI is contraindicated in pregnancy. First trimester: Major congenital malformations including neural tube defects and cardiac anomalies. Second and third trimesters: Fetal growth restriction, oligohydramnios, neonatal nephrotoxicity, and persistent pulmonary hypertension. Risk is dose-dependent and increases with duration of exposure. |
| Fetal Monitoring | Monitor maternal renal function, serum electrolytes, and blood pressure weekly. Perform serial fetal ultrasounds for growth and amniotic fluid volume. Monitor for signs of fetal distress. After birth, monitor neonatal renal function and electrolytes. |
| Fertility Effects | XROMI may impair female fertility based on animal studies showing reduced implantation and increased pre- and post-implantation loss. Reversible upon discontinuation. Effects on male fertility unknown. |
| Clinical Pearls | XROMI (hypothetical drug) is a prodrug requiring hepatic activation; monitor liver function tests. Dosing adjustment needed in renal impairment (CrCl <30 mL/min). Avoid in patients with history of QT prolongation. Onset of action is 30-60 minutes; maximal effect at 4 hours. Half-life is 12 hours in healthy adults, extended in elderly. |
| Patient Advice | Take XROMI with a full glass of water; do not crush or chew tablets. · Avoid alcohol while taking XROMI as it may increase risk of hepatotoxicity. · Report any signs of liver problems: yellowing of skin/eyes, dark urine, severe fatigue. · May cause dizziness or drowsiness; avoid driving until you know how the drug affects you. · Do not stop abruptly without consulting your doctor; taper under medical supervision. |